Showing 2663 results
Media Library /- Biography /
- Media Release /In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2…
Story /Dr Bülent Kızıltan, Global Head of AI & Computational Sciences
- Media Release /Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic…